ADMA Biologics
ADMA
347 hedge funds and large institutions have $4.07B invested in ADMA Biologics in 2025 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 128 increasing their positions, 113 reducing their positions, and 38 closing their positions.
312% more call options, than puts
Call options by funds: $67.2M | Put options by funds: $16.3M
76% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 38
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
16% more capital invested
Capital invested by funds: $3.5B → $4.07B (+$573M)
13% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 113
8% more funds holding
Funds holding: 322 → 347 (+25)
0.47% more ownership
Funds ownership: 86.32% → 86.79% (+0.47%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$31.4M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$28.9M |
| 3 |
RIM
Ranger Investment Management
Dallas,
Texas
|
+$27.7M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$27.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$27.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$59.3M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$28.5M |
| 3 |
D.E. Shaw & Co
New York
|
-$26.7M |
| 4 |
ACM
Altium Capital Management
New York
|
-$23.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23.5M |
ADMA Hedge Fund Activity: Q1 2025 in Review
347 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2025, worth a combined $4.07B — up 16% from $3.5B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new ADMA positions and 38 closed out — a net gain of 29 holders — while 128 added to existing stakes and 113 trimmed.
The largest buyer was UBS Group, adding an estimated $31.4M. The largest seller was State Street, cutting an estimated $59.3M.
- 347 institutional investors held ADMA Biologics (ADMA) as of Q1 2025, up from 322 in Q4 2024.
- Funds reported $4.07B of ADMA Biologics stock for Q1 2025, up 16% quarter-over-quarter.
- 67 funds opened new ADMA Biologics positions in Q1 2025 and 38 closed out, a net change of +29 holders.
- The largest ADMA Biologics buyer in Q1 2025 was UBS Group, an estimated $31.4M added.
- The largest ADMA Biologics seller in Q1 2025 was State Street, an estimated $59.3M sold.
Based on aggregated 13F filings for Q1 2025.